# Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

> **NCT00397189** · PHASE3 · COMPLETED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 930 (actual)

## Conditions studied

- Primary Insomnia

## Interventions

- **DRUG:** Circadin
- **DRUG:** placebo circadin

## Key facts

- **NCT ID:** NCT00397189
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-12
- **Final completion:** 2009-04
- **Target enrollment:** 930 (ACTUAL)
- **Last updated:** 2018-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00397189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00397189, "Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00397189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*